Beyond Air (NASDAQ:XAIR) Shares Down 2.1% – Should You Sell?

Beyond Air, Inc. (NASDAQ:XAIR)’s share price traded down 2.1% during trading on Thursday. The stock traded as low as $2.30 and last traded at $2.31. 16,525 shares traded hands during trading, a decline of 50% from the average daily volume of 32,752 shares. The stock had previously closed at $2.36.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on XAIR shares. Lake Street Capital assumed coverage on shares of Beyond Air in a research note on Tuesday, September 1st. They issued a “buy” rating and a $10.00 price objective on the stock. Weiss Ratings upgraded shares of Beyond Air from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $105.00.

Beyond Air Stock Performance

The stock has a 50 day moving average of $3.04 and a two-hundred day moving average of $10.77. The stock has a market capitalization of $2.15 million, a PE ratio of -0.03 and a beta of 0.21. The company has a debt-to-equity ratio of 7.81, a current ratio of 3.31 and a quick ratio of 3.12.

Beyond Air (NASDAQ:XAIR) last released its quarterly earnings data on Thursday, August 13th. The company reported ($11.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($10.80) by ($0.20). Beyond Air had a negative return on equity of 440.26% and a negative net margin of 435.71%. The business had revenue of $1.77 million during the quarter, compared to analysts’ expectations of $1.93 million.

Beyond Air Company Profile

Beyond Air, Inc is a medical technology and biopharmaceutical company focused on developing nitric oxide (NO) therapies and delivery systems for respiratory diseases and other serious medical conditions. Its platform is designed to generate NO from ambient air at the point of care, potentially reducing reliance on traditional high-pressure gas cylinders.

The company’s primary product family is LungFit, a series of compact NO delivery systems intended for use in hospital and clinical settings.